Description
Title: Preeclampsia’s pathogenesis and placenta-specific therapeutic strategies
Abstract: Around 5-7% of pregnancies experience preeclampsia (PE), a serious pregnancy complication that is marked by hypertension and damage to several maternal organs, primarily the liver and kidneys. PE typically starts after 20 weeks of pregnancy and, if untreated, can result in serious issues, lifelong disabilities, and even death for both the mother and the child. Since there is no treatment for the disease other than delivery, managing blood pressure and other clinical symptoms is the main goal of treatment. PE’s pathogenesis is still a mystery. PE is thought to have a number of primary pathologies, including abnormal spiral artery remodeling, placental ischemia, and a resulting rise in blood levels of vascular endothelial growth factor receptor-1 (VEGFR-1), also known as soluble fms-like tyrosine kinase-1 (sFlt-1). The decoy receptor sFlt-1, which is primarily made in the placenta during pregnancy, binds to both free VEGF (VEGF-A) and placental growth factor (PlGF), reducing their bioavailability to target cells. Recent research from our lab and others has strongly suggested that the increase in sFlt-1 in PE may fulfill important protective functions in preeclamptic pregnancies, despite the pathogenic effects of increased sFlt-1 on the maternal vasculature. To develop therapeutic approaches that target VEGF signaling for the treatment of PE, additional research on the functions of sFlt-1 in healthy and preeclamptic pregnancies is therefore necessary. Since PE is thought to have a placental origin and the majority of treatment options have negative side effects on both the mother and the fetus, this is another barrier to effective PE treatment. The current evaluation the recently created placenta-targeted drug delivery system for the potential treatment of PE with candidate therapeutic agents, the complex role of sFlt-1 in maternal disease and fetal protection, and the pathogenesis of PE.
Keywords: preeclampsia; pathogenesis; cytotrophoblasts; placenta; spiral artery
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Biomolecules
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.